Patents by Inventor Claude Dufresne

Claude Dufresne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl diol acids as leukotriene antagonists
    Patent number: 5750539
    Abstract: Compounds of Formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 12, 1998
    Assignee: Merck Frosst Canada
    Inventors: Yves Gareau, Claude Dufresne, Marc Labelle, James Yergey, Xin Xu, Deborah Nicoll-Griffith, Nathalie Chauret, Laird Trimble
  • Cholesterol lowering compounds
    Patent number: 5506262
    Abstract: Disclosed herein are compounds of structural formula (I) ##STR1## which are useful as cholesterol lowering agents. These compounds are also useful as inhibitors of squalene synthetase, inhibitors of fungal growth, inhibitors of farnesyl-protein transferase and farnesylation of the oncogene protein Ras. These compounds are also useful in the treatment of cancer.
    Type: Grant
    Filed: November 10, 1993
    Date of Patent: April 9, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Robert M. Burk, William H. Parsons, John J. Acton, III, Gregory D. Berger, Tesfaye Biftu, Robert L. Bugianesi, Yuan-Ching P. Chiang, Claude Dufresne, Narindar N. Girotra, Robert W. Marquis, Jr., Chan-Hwa Kuo, Sandra P. Plevyak, Mitree M. Ponpipom, Lori L. Whiting, James D. Bergstrom, Conrad Santini
  • Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
    Patent number: 5472964
    Abstract: Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: December 5, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Robert N. Young, Marc Labelle, Yves Leblanc, Yi B. Xiang, Cheuk K. Lau, Claude Dufresne, Yves Gareau
  • Aza-5,5-fused hetrocyclic acids as leukotriene antagonists
    Patent number: 5350760
    Abstract: Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: August 4, 1993
    Date of Patent: September 27, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark LaBelle, Yibin Xiang, Claude Dufresne, Michel Belley
  • Cholesterol lowering compounds
    Patent number: 5310949
    Abstract: New Zaragozic acids have been isolated from a culture of MF5465. These compounds and their derivatives are active as squalene synthetase inhibitors and are useful in the treatment of hypercholesterolemia.
    Type: Grant
    Filed: September 2, 1992
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Claude Dufresne, Prakash S. Masurekar, Leslie A. Ferrell, Deborah L. Zink, Margaret S. Sosa
  • Cholesterol-lowering agents
    Patent number: 5283256
    Abstract: This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthase inhibitors and thus useful as cholesterol lowering agents and antifungal agents. These compounds are also inhibitors of farnesyl protein transferase and farnesylation of the oncogene protein Ras and thus useful in treating cancer. This invention also relates to a process for obtaining compounds of structural formula (I).
    Type: Grant
    Filed: July 22, 1992
    Date of Patent: February 1, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Claude Dufresne, Josep Guarro, Leeyuan Huang, Yu L. Kong, Russell B. Lingham, Maria S. Meinz, Keith C. Silverman, Sheo B. Singh
  • Cholesterol lowering compounds
    Patent number: 5260332
    Abstract: New Zaragozic acids have been isolated from a culture of MF5465. These compounds and their derivatives are active as squalene synthetase inhibitors and are useful in the treatment of hypercholesterolemia.
    Type: Grant
    Filed: February 7, 1992
    Date of Patent: November 9, 1993
    Assignee: Merci & Co., Inc.
    Inventor: Claude Dufresne
  • Acyclic tricarboxylic acid compounds
    Patent number: 5254727
    Abstract: Two acyclic tricarboxylic acid compounds have been isolated from the fermentation of Sporormiella intermedia. The compounds and their derivatives may be used as antifungal agents, cholesterol lowering agents and as anticancer agents.
    Type: Grant
    Filed: October 19, 1992
    Date of Patent: October 19, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Claude Dufresne, E. Tracy T. Jones, Leslie A. Ferrell
  • Quinoline-substituted chromans and related compounds as leukotriene antagonists
    Patent number: 5149703
    Abstract: Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: September 6, 1991
    Date of Patent: September 22, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cheuk K. Lau, Claude Dufresne
  • Squalene synthetase inhibitors
    Patent number: 5132320
    Abstract: This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthetase inhibitors and thus useful as cholesterol lowering agents.
    Type: Grant
    Filed: March 21, 1990
    Date of Patent: July 21, 1992
    Assignee: Merck & Co., Inc.
    Inventors: James D. Bergstrom, Otto D. Hensens, Claude Dufresne, Leeyuan Huang, Janet C. Onishi, Deborah L. Zink
  • Novel squalene synthetase inhibitors
    Patent number: 5102907
    Abstract: This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthetase inhibitors and thus useful as cholesterol lowering agents.
    Type: Grant
    Filed: September 13, 1990
    Date of Patent: April 7, 1992
    Assignee: Merck & Co., Inc.
    Inventors: James D. Bergstrom, Claude Dufresne, Leeyuan Huang, Mary Nallin, Janet C. Onishi
  • 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors
    Patent number: 5091533
    Abstract: Compounds of the formula: ##STR1## where R.sup.2 contains certain aryls or heteroaryls are effective leukotriene inhibitors.
    Type: Grant
    Filed: March 12, 1990
    Date of Patent: February 25, 1992
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Patrice C. Belanger, Claude Dufresne, Brian Fitzsimmons, deceased, Maryann Fitzsimmons, Heir, Yvan Guindon, Cheuk K. Lau, Joshua Rokach, John Schiegetz, Michel Therien, Robert N. Young
  • Process for preparing substituted phenylalkenoic acids
    Patent number: 4453005
    Abstract: Substituted phenylalkenoic acids and esters of the formula: ##STR1## having useful pharmaceutical activity and processes for their preparation are disclosed.
    Type: Grant
    Filed: December 6, 1982
    Date of Patent: June 5, 1984
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Patrice C. Belanger, Claude Dufresne, John W. Gillard, Haydn W. R. Williams